NUVL vs. ALPN, MDGL, ALKS, PRGO, CRNX, INSM, HCM, AXSM, PBH, and APLS
Should you be buying Nuvalent stock or one of its competitors? The main competitors of Nuvalent include Alpine Immune Sciences (ALPN), Madrigal Pharmaceuticals (MDGL), Alkermes (ALKS), Perrigo (PRGO), Crinetics Pharmaceuticals (CRNX), Insmed (INSM), HUTCHMED (HCM), Axsome Therapeutics (AXSM), Prestige Consumer Healthcare (PBH), and Apellis Pharmaceuticals (APLS). These companies are all part of the "pharmaceutical preparations" industry.
Alpine Immune Sciences (NASDAQ:ALPN) and Nuvalent (NASDAQ:NUVL) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, community ranking, profitability, risk, media sentiment, earnings and valuation.
75.2% of Alpine Immune Sciences shares are held by institutional investors. Comparatively, 97.3% of Nuvalent shares are held by institutional investors. 42.3% of Alpine Immune Sciences shares are held by insiders. Comparatively, 14.8% of Nuvalent shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Nuvalent has a net margin of 0.00% compared to Nuvalent's net margin of -65.17%. Nuvalent's return on equity of -14.86% beat Alpine Immune Sciences' return on equity.
Alpine Immune Sciences received 354 more outperform votes than Nuvalent when rated by MarketBeat users. However, 71.43% of users gave Nuvalent an outperform vote while only 64.46% of users gave Alpine Immune Sciences an outperform vote.
Alpine Immune Sciences has a beta of 0.97, meaning that its stock price is 3% less volatile than the S&P 500. Comparatively, Nuvalent has a beta of 1.35, meaning that its stock price is 35% more volatile than the S&P 500.
Alpine Immune Sciences presently has a consensus price target of $52.33, indicating a potential downside of 19.45%. Nuvalent has a consensus price target of $90.78, indicating a potential upside of 28.07%. Given Alpine Immune Sciences' stronger consensus rating and higher probable upside, analysts clearly believe Nuvalent is more favorable than Alpine Immune Sciences.
Alpine Immune Sciences has higher revenue and earnings than Nuvalent. Alpine Immune Sciences is trading at a lower price-to-earnings ratio than Nuvalent, indicating that it is currently the more affordable of the two stocks.
In the previous week, Nuvalent had 5 more articles in the media than Alpine Immune Sciences. MarketBeat recorded 14 mentions for Nuvalent and 9 mentions for Alpine Immune Sciences. Nuvalent's average media sentiment score of 1.26 beat Alpine Immune Sciences' score of 0.84 indicating that Alpine Immune Sciences is being referred to more favorably in the media.
Summary
Nuvalent beats Alpine Immune Sciences on 9 of the 17 factors compared between the two stocks.
Get Nuvalent News Delivered to You Automatically
Sign up to receive the latest news and ratings for NUVL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NUVL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Nuvalent Competitors List
Related Companies and Tools
